The Skeletal Question: Do GLP-1 Agonists Pose a Risk to Bone Health?
Ali Ikhwan
For millions of Americans navigating the complexities of obesity and type 2 diabetes, the emergence of GLP-1 receptor agonists—branded as Ozempic, Wegovy, and Zepbound—has been nothing short of revolutionary. These…
